MarginsXMarginsX
Home › Markets › Health Care › XNCR

Xencor Inc. (XNCR)

XNCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$35.40
-4.56% on the day
Market cap
$2.7B
Mid cap
Revenue · 2025
$125.6M
+13.7% on 2024
Net income · 2025
-$91.9M
-73.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1326732/000132673226000015/0001326732-26-000015-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerXNCR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2013
SEC CIK0001326732
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$125.6M
Net income-$91.9M
Operating income-$177.5M
Net margin-73.2%
Operating margin-141.4%
Revenue growth+13.7%
Cash$54.1M
Total assets$875.5M
P/E (computed)Net income was not positive
P/S (computed)21.2×

Warning signs

Cash runway
4.2 months
$59.6M cash at September 30, 2026
Share count, 1 year
+5.1%
2025-10-30 to 2026-10-30 · +23.3% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$3.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$59.6M cash; operating cash flow -$43.1M a quarter.Report 2026-09-30
Shares outstanding75,039,689 (2026-10-30); 71,410,469 a year earlier; 60,875,198 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-02-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Diego, California, United States; changed auditors 2 times in 24 months8-K 4.01 2025-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $3.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$116.5M$39.4M$2.6M$59.6M$95.1M$200.5M10-Q 2026-11-04
Q2 2026
2026-06-30
$51.2M-$21.7M-$55.7M$44.7M$104.9M$105.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$4.5M-$128.9M-$67.6M$14.2M$108.5M$97.4M10-Q 2026-05-06
Q4 2025
2025-12-31
$28.2M-$6.7M-$51.7M$54.1M$119.7M$125.6M10-K 2026-02-25
Q3 2025
2025-09-30
$21.0M-$6.0M-$30.8M$28.3M$133.1M$150.1M10-Q 2026-11-04
Q2 2025
2025-06-30
$43.6M-$30.8M-$36.4M$44.4M$145.0M$146.9M10-Q 2026-08-05
Q1 2025
2025-03-31
$32.7M-$48.4M-$16.2M$39.7M$154.4M$127.2M10-Q 2026-05-06
Q4 2024
2024-12-31
$52.8M-$45.6M-$49.8M$40.9M$163.6M$110.5M10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-02-25
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 903 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.7%
1 month+57.7%
3 months+61.3%
Year to date+142.3%
1 year+165.1%
From 52-week high-7.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZLABZai Lab Limited$23.47-4.59%$2.6B
MBXMBX Biosciences Inc.$53.12-5.04%$2.6B
HCMHUTCHMED (China) Limited$14.73-1.14%$2.6B
VCREVicore Pharma Holding AB$10.16-1.93%$2.9B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
IDYAIDEAYA Biosciences Inc.$30.36-4.62%$2.9B
TLXTelix Pharmaceuticals Limited$8.92-3.36%$3.0B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier